Zilucoplan

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 80 publications

Nipocalimab (Imaavy) for myasthenia gravis.

Nipocalimab (Imaavy) for myasthenia gravis.

Journal: The Medical letter on drugs and therapeutics

Published: May 15, 2026

Real-world effectiveness and safety of zilucoplan in patients with anti-AChR myasthenia gravis: A retrospective cohort study in France.

Real-world effectiveness and safety of zilucoplan in patients with anti-AChR myasthenia gravis: A retrospective cohort study in France.

Journal: Journal of neuromuscular diseases

Published: March 29, 2026

Combined inhibition of complement C5 and neonatal Fc receptor in refractory generalized myasthenia gravis: A report of two cases.

Combined inhibition of complement C5 and neonatal Fc receptor in refractory generalized myasthenia gravis: A report of two cases.

Journal: Journal of neuroimmunology

Published: February 07, 2026

Rapid Symptomatic Improvement and Long-Term Minimal Symptom Expression in a Myasthenia Gravis Patient Treated With Zilucoplan Without Maintenance Cholinesterase Inhibitors, Corticosteroids, or Immunosuppressants: A Case Report.

Rapid Symptomatic Improvement and Long-Term Minimal Symptom Expression in a Myasthenia Gravis Patient Treated With Zilucoplan Without Maintenance Cholinesterase Inhibitors, Corticosteroids, or Immunosuppressants: A Case Report.

Journal: Cureus

Published: January 28, 2026

Authors' reply to comment letter on ZILU25 study.

Authors' reply to comment letter on ZILU25 study.

Journal: Journal of the neurological sciences

Published: January 13, 2026

Novel Therapies for Generalized Myasthenia Gravis: Insights Into FcRn and Complement Inhibition.

Novel Therapies for Generalized Myasthenia Gravis: Insights Into FcRn and Complement Inhibition.

Journal: American journal of therapeutics

Published: January 08, 2026

Letter to the editor: Early real-life experience on Zilucoplan for generalized myasthenia gravis: ZILU25 multicenter observational study.

Letter to the editor: Early real-life experience on Zilucoplan for generalized myasthenia gravis: ZILU25 multicenter observational study.

Journal: Journal of the neurological sciences

Published: January 08, 2026

Efficacy and safety of complement inhibitors and FcRn blockers in generalized AChR antibody-positive myasthenia gravis: a meta-analysis.

Efficacy and safety of complement inhibitors and FcRn blockers in generalized AChR antibody-positive myasthenia gravis: a meta-analysis.

Journal: Journal of neurology

Published: January 06, 2026

Letter to editor: Early real-life experience on zilucoplan for generalized myasthenia gravis: ZILU25 multicenter observational study.

Letter to editor: Early real-life experience on zilucoplan for generalized myasthenia gravis: ZILU25 multicenter observational study.

Journal: Journal of the neurological sciences

Published: January 02, 2026

Body weight distribution of US patients with myasthenia gravis.

Body weight distribution of US patients with myasthenia gravis.

Journal: Journal of medical economics

Published: December 21, 2025

Meningococcal prophylaxis in neurological diseases treated with complement inhibitors: an expert consensus for Germany, Austria, and Switzerland.

Meningococcal prophylaxis in neurological diseases treated with complement inhibitors: an expert consensus for Germany, Austria, and Switzerland.

Journal: Therapeutic advances in neurological disorders

Published: December 17, 2025

Comments on ZILU25: Real-world efficacy of Zilucoplan in generalized myasthenia gravis.

Comments on ZILU25: Real-world efficacy of Zilucoplan in generalized myasthenia gravis.

Journal: Journal of the neurological sciences

Published: December 11, 2025

Showing 1-12 of 80

Last Updated: 06/30/2026